Quoin Pharmaceuticals Ltd Stock Today

QNRX Stock  USD 5.37  0.12  2.19%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Very High

 
High
 
Low
Quoin Pharmaceuticals is trading at 5.37 as of the 13th of April 2025; that is 2.19 percent decrease since the beginning of the trading day. The stock's open price was 5.49. Quoin Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 14th of March 2025 and ending today, the 13th of April 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
29th of July 2016
Category
Healthcare
Classification
Health Care
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Quoin Pharmaceuticals, Ltd. was incorporated in 2018 and is based in Ashburn, Virginia. The company has 588.17 K outstanding shares of which 174.01 K shares are at this time shorted by private and institutional investors with about 0.23 trading days to cover. More on Quoin Pharmaceuticals Ltd

Moving together with Quoin Stock

  0.73VANI Vivani MedicalPairCorr

Moving against Quoin Stock

  0.68VALN Valneva SE ADRPairCorr

Quoin Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.11.3
Fairly Down
Very volatile
Total Current Liabilities4.4 B4.2 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total2.4 B2.3 B
Sufficiently Up
Slightly volatile
Total Assets16.5 B15.7 B
Sufficiently Up
Slightly volatile
Total Current Assets15.7 B14.9 B
Sufficiently Up
Slightly volatile
Debt Levels
Quoin Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Quoin Pharmaceuticals' financial leverage. It provides some insight into what part of Quoin Pharmaceuticals' total assets is financed by creditors.
Liquidity
Quoin Pharmaceuticals Ltd currently holds 6.5 B in liabilities with Debt to Equity (D/E) ratio of 0.47, which is about average as compared to similar companies. Quoin Pharmaceuticals has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Quoin Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Total Cash From Financing Activities

11.52 Billion
Quoin Pharmaceuticals Ltd (QNRX) is traded on NASDAQ Exchange in USA. It is located in 42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349 and employs 3 people. Quoin Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.16 M. Quoin Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 588.17 K outstanding shares of which 174.01 K shares are at this time shorted by private and institutional investors with about 0.23 trading days to cover. Quoin Pharmaceuticals Ltd currently holds about 2.69 M in cash with (7.86 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56.
Check Quoin Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Quoin Pharmaceuticals holds 7.07 pct. of its outstanding shares held by insiders and 7.51 pct. owned by third-party entities.
Check Quoin Ownership Details

Quoin Stock Institutional Holders

InstituionRecorded OnShares
Ubs Group Ag2024-12-31
4.8 K
Sbi Securities Co Ltd2024-12-31
24.0
Raiffeisen Bank International Ag2024-12-31
17.0
Resources Investment Advisors Inc2024-09-30
0.0
Susquehanna International Group, Llp2024-09-30
0.0
Jpmorgan Chase & Co2024-12-31
0.0
Two Sigma Investments Llc2024-09-30
0.0
Virtu Financial Llc2024-12-31
0.0
Bank Of America Corp2024-09-30
0.0
Armistice Capital, Llc2024-12-31
530 K
Altium Capital Management, Lp2024-12-31
282.2 K
View Quoin Pharmaceuticals Diagnostics

Quoin Pharmaceuticals Historical Income Statement

At this time, Quoin Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Research Development is likely to rise to about 3.8 B in 2025, whereas Gross Profit is likely to drop (124.9 K) in 2025. View More Fundamentals

Quoin Stock Against Markets

Additional Tools for Quoin Stock Analysis

When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.